PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.95%
Revenue growth of 5.95% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
9.53%
Gross profit growth of 9.53% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
43.67%
EBIT growth of 43.67% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
30.10%
Operating income growth of 30.10% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
42.72%
Net income growth of 42.72% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
42.72%
EPS growth of 42.72% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
42.72%
Diluted EPS growth of 42.72% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.07%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.78%
10Y CAGR of 22.78% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
-7.65%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
35.01%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 1.24%. Joel Greenblatt might see a short-term competitive advantage at play.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.39%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 41.84% over a decade. Joel Greenblatt might see a standout compounder of earnings.
2.81%
5Y net income/share CAGR 1.25-1.5x Medical - Pharmaceuticals median. Mohnish Pabrai would check that top-line growth and share count management both contribute.
47.84%
3Y net income/share CAGR of 47.84% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
No Data
No Data available this quarter, please select a different quarter.
28.23%
5Y equity/share CAGR 75-90% of Medical - Pharmaceuticals median. John Neff calls for higher returns or more efficient buybacks to match peers.
68.77%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 33.90%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
-100.00%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-99.16%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-2.48%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
1.44%
We expand assets while Medical - Pharmaceuticals is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
5.18%
Positive BV/share change while Medical - Pharmaceuticals median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-25.72%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
101.71%
SG&A growth of 101.71% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.